Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 14, 2016; 22(26): 6008-6015
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.6008
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.6008
Table 1 Pulmonary hypertension; drug classification
| Classification | Name | Mechanism of action |
| Endothelin receptor antagonist | Bosentan | Dual ETA and ETB receptor subtypes antagonist. Specifically, inhibition of ET-1 receptors |
| Ambrisentan | Highly selective ETA receptor inhibition | |
| Macitentan | High affinity ETA than ETB antagonist. | |
| Phosphodiesterase 5 inhibitors | Sildenafil | High selectivity for PD5 vs PD2, 3 and 4. |
| Tadalafil | High selectivity for PD5 compared with PD1, 4, 7 and 10. | |
| Prostanoids | Epoprostenol | Synthetic prostacyclin with potent effects of vasodilatation and platelet aggregator inhibitor. |
| Treprostinil | Long acting tricyclic benzindene synthetic analogue of prostacyclin. Vasodilator and inhibits platelet inhibition. |
Table 2 Differences between the hepatopulmonary syndrome and portopulmonary hypertension
| Hepatopulmonary syndrome | Portopulmonary hypertension | |
| Pathophysiology | Severe vasodilatation | Severe vasoconstriction |
| Production of endothelin-1 and tumor necrosis alpha and eNOS and iNOS | Concentric intimal fibrosis, and smooth muscle hyperplasia and hypertrophy | |
| Increase of CO | Endothelin-1, prostacyclin and thromboxane | |
| Vasculoendothelial growth factor-A | ||
| Angiogenesis | ||
| Clinical features | Most patients are asymptomatic | Dyspnea |
| Dyspnea | Orthopnea | |
| Platypnea | Fatigue | |
| Orthodeoxia | Syncope | |
| Significant sleep-time oxygen desaturation | Chest pain | |
| Lightheadedness | ||
| Tricuspid regurgitation murmur, with a pronounced P2 sound | ||
| Increased jugular venous pressure | ||
| Peripheral edema | ||
| Ascites | ||
| Diagnosis | Corrected alveolar-arterial oxygen gradient (Abnormal if > 15-20 mmHg) with or without hypoxemia (PaO2), all in sitting position | Transthoracic echocardiography. |
| Contrast-enhanced echocardiography | ||
| Degree of severity: Alveolar-Arterial oxygen gradient > 15 mmHg,mild with PaO2 > 80 mmHg, moderate > 60 mmHg to < 80 mmHg, severe > 50 mmHg to < 60 mmHg or very severe < 50 mmHg | ||
| Pulmonary angiography | ||
| Treatment | Liver transplant | Endothelin receptor antagonist, phosphodiesterase type-5inhibitors, prostanoids, and combination therapy |
| Sildenafil alone or combined with prostacyclins | ||
| Transjugular intrahepatic portosystemic shunting | ||
| Liver transplant |
- Citation: Surani SR, Mendez Y, Anjum H, Varon J. Pulmonary complications of hepatic diseases. World J Gastroenterol 2016; 22(26): 6008-6015
- URL: https://www.wjgnet.com/1007-9327/full/v22/i26/6008.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i26.6008
